z-logo
Premium
From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France
Author(s) -
Lefrère JeanJacques,
Hewitt Patricia
Publication year - 2009
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2008.02044.x
Subject(s) - medicine , blood transfusion , leukoreduction , transmission (telecommunications) , blood donations , disease , donation , population , deferral , intensive care medicine , immunology , environmental health , business , electrical engineering , accounting , economics , engineering , economic growth
Transfusion transmission of the prion, the agent of variant Creutzfeldt‐Jakob disease (vCJD), is now established. Subjects infected through food may transmit the disease through blood donations. The two nations most affected to date by this threat are the United Kingdom (UK) and France. The first transfusion cases have been observed in the UK over the past 5 years. In France, a few individuals who developed vCJD had a history of blood donation, leading to a risk of transmission to recipients, some of whom could be incubating the disease. In the absence of a large‐scale screening test, it is impossible to establish the prevalence of infection in the blood donor population and transfused patients. This lack of a test also prevents specific screening of blood donations. Thus, prevention of transfusion transmission essentially relies at present on deferral of “at‐risk” individuals. Because prions are present in both white blood cells and plasma, leukoreduction is probably insufficient to totally eliminate the transfusion risk. In the absence of a screening test for blood donations, recently developed prion‐specific filters could be a solution. Furthermore, while the dietary spread of vCJD seems efficiently controlled, uncertainty remains as to the extent of the spread of prions through blood transfusion and other secondary routes.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here